Ajanta Pharma Ltd
Fundamental Score
Ajanta Pharma Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of AJANTPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (24.91%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.37%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (27.53%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (20.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Consistent Growth Track Record (12.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (15.34% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (56.18x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹2953.50 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (66.24%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 26.43%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
1 factors identified
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Ajanta Pharma Ltd
About AJANTPHARM
Business Overview
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
AJANTPHARM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Ajanta Pharma Ltd (AJANTPHARM)?
As of 30 Jan 2026, 01:39 pm IST, Ajanta Pharma Ltd (AJANTPHARM) is currently trading at ₹2781.90. The stock has a market capitalization of ₹32.08K (Cr).
Is AJANTPHARM share price Overvalued or Undervalued?
AJANTPHARM is currently trading at a P/E ratio of 32.94x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Ajanta Pharma Ltd share price?
Key factors influencing AJANTPHARM's price include its quarterly earnings growth (Sales Growth: 14.08%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ajanta Pharma Ltd a good stock for long-term investment?
Ajanta Pharma Ltd shows a 5-year Profit Growth of 14.26% and an ROE of 24.91%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.06 before investing.
How does Ajanta Pharma Ltd compare with its industry peers?
Ajanta Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare AJANTPHARM's P/E of 32.94x and ROE of 24.91% against the industry averages to determine its competitive standing.
What is the P/E ratio of AJANTPHARM and what does it mean?
AJANTPHARM has a P/E ratio of 32.94x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹33 for every ₹1 of annual earnings.
How is AJANTPHARM performing according to Bull Run's analysis?
AJANTPHARM has a Bull Run fundamental score of 53.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does AJANTPHARM belong to?
AJANTPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ajanta Pharma Ltd.
What is Return on Equity (ROE) and why is it important for AJANTPHARM?
AJANTPHARM has an ROE of 24.91%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Ajanta Pharma Ltd generates profits from shareholders' equity.
How is AJANTPHARM's debt-to-equity ratio and what does it indicate?
AJANTPHARM has a debt-to-equity ratio of 0.06, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is AJANTPHARM's dividend yield and is it a good dividend stock?
AJANTPHARM offers a dividend yield of 1.09%, which means you receive ₹1.09 annual dividend for every ₹100 invested.
How has AJANTPHARM grown over the past 5 years?
AJANTPHARM has achieved 5-year growth rates of: Sales Growth 12.43%, Profit Growth 14.26%, and EPS Growth 15.34%.
What is the promoter holding in AJANTPHARM and why does it matter?
Promoters hold 66.24% of AJANTPHARM shares, with 15.28% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is AJANTPHARM's market capitalization category?
AJANTPHARM has a market capitalization of ₹32076 crores, placing it in the Large-cap category.
How volatile is AJANTPHARM stock?
AJANTPHARM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for AJANTPHARM?
AJANTPHARM has a 52-week high of ₹N/A and low of ₹N/A.
What is AJANTPHARM's operating profit margin trend?
AJANTPHARM has a 5-year average Operating Profit Margin (OPM) of 27.53%, indicating the company's operational efficiency.
How is AJANTPHARM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 14.08% and YoY Profit Growth of 20.19%.
What is the institutional holding pattern in AJANTPHARM?
AJANTPHARM has FII holding of 8.53% and DII holding of 17.90%. Significant institutional holding often suggests professional confidence in the stock.